Optibiotix Health has successfully raised US$1.3 million though a placing of new shares
Optibiotix Health Plc has completed a fundraising to continue the commercialization of its products with corporate and large retail partners, with a particular focus on the company’s SweetBiotix©.
OptiBiotix Health is a life sciences company operating in one of the most progressive areas of biotechnological research. Developing technologies that modulate the human microbiome – the collective genome of the microbes in the body – OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. With an established pipeline of microbiome modulators, the OptiBiotix team is working in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles and diabetes.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Optibiotix Health on its equity fundraising.
Talk to the deal team
Related deals
AMC Media Group has been acquired by Formedics
AMC Media Group, a health care professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician's Weekly and OncWeekly.
Learn moreBellefleur has been acquired by Domidep
Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.
Learn moreUnitary Healthcare has been acquired by Axel Health
Axel Health Oy, headquartered in Finland, has acquired the Finnish software company Unitary Healthcare Oy.
Learn more